A single-center, single-arm, prospective, open-label trial to evaluate the efficacy and safety of percutaneous sclerotherapy with polidocanol for painful venous malformations (SCIRO-2001): study protocol

This single-center, single-arm, prospective open-label trial is being conducted to evaluate the short-term efficacy and safety of percutaneous sclerotherapy with polidocanol foam for painful venous malformations. This study will include patients who were clinically diagnosed with venous malformation...

Full description

Saved in:
Bibliographic Details
Published in:Nagoya journal of medical science 2022-11, Vol.84 (4), p.746-751
Main Authors: Uka, Mayu, Sakurai, Jun, Matsui, Yusuke, Iguchi, Toshihiro, Tomita, Koji, Umakoshi, Noriyuki, Munetomo, Kazuaki, Mitsuhashi, Toshiharu, Gobara, Hideo, Hiraki, Takao
Format: Article
Language:English
Subjects:
Original Paper
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This single-center, single-arm, prospective open-label trial is being conducted to evaluate the short-term efficacy and safety of percutaneous sclerotherapy with polidocanol foam for painful venous malformations. This study will include patients who were clinically diagnosed with venous malformation by using ultrasound and/or magnetic resonance imaging, and whose pain persisted even after treatment with medications. Written informed consent for sclerotherapy will be obtained from all patients. The institutional review board approved this prospective study protocol. The primary endpoint is pain relief at three months after sclerotherapy. Local pain related to venous malformation will be evaluated using a numeric rating scale. Patient recruitment commenced in December of 2020. Enrolment of 13 patients is planned over a 3-year recruitment period. Herein, we describe the details of the clinical trial protocol.
ISSN:0027-7622
2186-3326
DOI:10.18999/nagjms.84.4.746